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1. ABSTRACT 
 
We previously reported that the innate sensing of the endosymbiont Leishmania RNA virus 1 (LRV1) within 
Leishmania (Viannia) guyanensis through Toll-like receptor 3, worsens the pathogenesis of parasite infection in mice. The 
presence of LRV1 has been associated with the failure of first-line treatment in patients infected with LRV1 containing -L. 
guyanensis and -L. braziliensis parasites. Here, we established a semi-automated image-based high-throughput drug screening 
(HTDS) protocol to measure parasiticidal activity of the Prestwick chemical library in primary murine macrophages infected with 
LRV1-containing L. guyanensis. The two-independent screens generated 14 hit compounds with over sixty-nine percent 
reduction in parasite growth compared to control, at a single dose in both screens. Our screening strategy offers great potential in 
the search for new drugs and accelerates the discovery rate in the field of drug repurposing against Leishmania. Moreover, this 
technique allows the concomitant assessment of the effect of drug toxicity on host cell number. 
 
2. INTRODUCTION 
 
Leishmania is an oblige intracellular protozoan parasite, which gives rise to a sand fly borne disease named 
leishmaniasis. Leishmaniasis may lead to symptomatic or asymptomatic primary cutaneous lesions at the site of inoculation. In 
addition to cutaneous lesions, Leishmania Viannia subgenus parasites can cause the metastatic types of leishmaniasis, namely 
mucocutaneous (MCL) and disseminated cutaneous (DCL) leishmaniasis (1). The underlying mechanism of metastatic 
leishmaniasis development remains largely unknown. Our previous studies show that the presence of an endosymbiotic double-
stranded RNA (dsRNA) virus, in L. guyanensis, named Leishmania RNA virus 1 (LRV1), increases the disease severity and 
accelerates parasite dissemination in mice (2-4). Moreover, LRV1 leads to first-line treatment failure and symptomatic relapse of 
L. guyanensis and L. braziliensis infections in humans (5, 6). 
 
Currently, no vaccination is available against leishmaniasis (7). There is a continuous and gradual increase in the 
prevalence of drug-resistant Leishmania spp. (8, 9). Current drug regimes against Leishmania parasites have severe side effects 
that can affect the quality of life of patients post-treatment. Furthermore, some treatment schemes require hospitalization, or 
trained personnel for intravenous administration (10-12). Thus, new drugs against leishmaniasis are required. 
 
Promastigote or axenic amastigote Leishmania parasites have previously been used in drug discovery studies (13). 
Although promastigotes are easy to culture and handle in a laboratory setting, parasites at this stage represent the vector-
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transmitted form of a parasite life cycle and do not biologically reflect intra-macrophage amastigotes. Moreover, the 
susceptibility of promastigotes and amastigotes to compounds may vary greatly (14). Thus, many potential anti-leishmanial 
compounds may be discarded during the initial screening against promastigotes due to their low parasiticidal activity. Axenic 
amastigotes on the other hand closely mimic the intracellular stage of the parasites, however, the host cell environment cannot be 
mimicked with these parasites (15). The interaction between the host cell and parasites is a crucial determining factor in the 
cellular fitness of parasites, this parameter should thus be taken into account when screening for new compounds. 
 
Macrophages are the terminal host of the Leishmania parasite (16). Thus, primary murine macrophages are a good cell 
model to mimic intracellular infection and are easy to produce in large quantities. These primary cells enable adequate 
assessment of potential compounds for anti-parasitic efficacy as well as toxicity to the host-cell (17, 18). The drawback of using 
an in vitro macrophage infection model is the laborious, bias, and error-prone manual counting technique that is used to calculate 
the parasiticidal activity of drugs by counting intracellular amastigotes within cells. 
 
Here, we introduced the method for an unbiased semi-automated image-based high-throughput drug screening (HTDS) 
against LRV1-bearing L. guyanensis within primary murine macrophages. We first optimized the in vitro conditions and 
developed an experimental pipeline, suitable for large-scale drug screening assays. We validated the method by evaluating the 
activity of the widely used anti-leishmanial drugs, namely amphotericin B and miltefosine. We subsequently screened the 
Prestwick chemical library using our established HTDS protocol. 
 
MATERIALS AND METHODS 
 
Ethical statement 
The animal protocol used in this study was approved by the Swiss Federal Veterinary Office (SFVO), under the 
authorization numbers 2113.1. and 2113.2. Animal handling and experimental procedures were undertaken in accordance with 
ethical guidelines determined by the SFVO and under inspection by the Department of Security and Environment of the State of 
Vaud, Switzerland. 
 
Bone-marrow derived macrophage production 
Tibias and femurs of naive C57BL/6 mice were washed with complete DMEM containing 10 percent FBS, 1 percent 
penicillin/streptomycin, and 1 percent HEPES to collect bone marrow. Cell suspensions were then filtered through a 40-
micrometer filter and centrifuged at 200xg for 8 minutes at 4 degrees Celsius. Cells were resuspended in complete DMEM, and 
then counted using a Vi-CELL Series Cell Viability Analyzer, and cultured with 50 ng/ml mouse recombinant macrophage 
colony stimulating factor (M-CSF) at a concentration of 7x105 cells/ml for 6 days. 5 ml complete DMEM supplemented with 50 
ng/ml rMCSF was added after 3 days of culture. On the sixth day, the medium was aspirated and cells were washed with ice-cold 
1xPBS, pH 7.4. containing 5mM EDTA to detach the cells. 
 
Flow cytometry analysis of bone-marrow derived macrophages 
Cells were resuspended in 100 microliter of staining solution, containing  an equal amount of FACS buffer (1xPBS 
with 2 percent FBS) and 24G2 conditioned medium. Cells were stained with anti-CD11b and anti-F4/80 antibodies for 30 
minutes. Samples were then washed with FACS buffer. FACS analysis was performed using a BD Accuri C6 or BD LSRII 
cytometer and analyzed in FlowJo (v9.7.5., TreeStar), or BD FACSDiva software. 
 
In vitro parasite culture 
LRV1 containing L. guyanensis (MHOM/BR/75/M4147) were used in this study. Promastigotes were cultured with 
Schneider’s insect medium supplemented with 20 percent heat-inactivated FBS and 50U/ml penicillin/streptomycin. Parasites 
were cultured at 26 degrees Celsius with 5 percent CO2 supply for 5-6 days. Stationary stat-phase promastigotes were used to 
infect macrophages. 
 
The plating and infection of macrophages 
100 microliters of macrophage suspension at a concentration 1.2.5x106 cells/ml were supplemented with 50 ng/ml of 
rMCSF and dispensed into clear-bottom 96-well plates using a Multidrop Combi Reagent Dispenser. Assay plates were then 
incubated at 37 degrees Celsius with a 5 percent CO2 supply overnight. Stationary promastigotes were centrifuged at 2000xg for 
10 min at room temperature. Parasites were resuspended in complete DMEM, and were counted using a counting chamber. 
Parasite concentration was adjusted to 12.5.x106 cells/ml in complete DMEM, supplemented with 50 ng/ml of rMCSF. 100 
microliters of promastigotes at a multiplicity of infection (MOI) of 10 were dispensed on top of macrophages using a Multidrop 
Combi Reagent Dispenser. Macrophages were incubated with parasites at 35 degrees Celsius with a 5 percent CO2 supply for 48 
hours. Cells were dispensed at the fine edge of the well to have a homogenous distribution of cells.  
 
3.6. Drug library preparation 
The Prestwick chemical library (PCL) was divided into sixteen assay plates. Tested compounds and controls were echo-
dispensed by Echo 550 (Labcyte), located in the Biomolecular screening facility (BSF) of the Ecole Polytechnique Fédérale de 
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Lausanne (EPFL). All compounds together with positive and negative controls were echo-dispensed into plates. The plates were 
then were stored at -20degrees Celsius. 
 
3.7. Compound library administration 
The compound plates were thawed and briefly centrifuged. Preheated complete DMEM was dispensed into wells using 
a Multidrop Combi Reagent Dispenser. Compound plates were then shook, briefly centrifuged, and aspirated using a Bravo 
Automated Liquid Handling Platform and dispensed on the middle of corresponding wells. All compounds were assayed at 10 
micromolar in this screening method. Plates were incubated at 35 degrees Celsius with a 5 percent CO2 supply for an additional 
48 hours. 
 
3.8. Staining and image acquisition 
Cells were subsequently fixed with freshly-made 4 percent paraformaldehyde (PFA) pH 7.4., for 15 minutes, pH 7.4., 
washed with 1xPBS then stained with DAPI (Molecular Probe®) and phalloidin-Alexa488 (Molecular Probe®) in 1xPBS using a 
Bio-Tek plate washer. Images were acquired using a 40x air-lens with a  high content microscope. 49 square images of 352.0.8 x 
352.0.8 micrometer size and 200 micrometer distance between them were taken in each well. MetaXpress and AcquityEpress 
software were used for image acquisition processing and consequent analysis.  
 
RESULTS 
 
The screening method was based on primary macrophages that were infected with L. guyanensis promastigotes at 
stationary phase. We used a well-established method to produce macrophages by incubating murine bone-marrow progenitors 
with macrophage-colony stimulating factor (M-CSF). As previously described, plated macrophages were incubated with medium 
containing M-CSF to enhance the cellular fitness of these primary cells during the screening (19). Current image-based drug 
screening assays require an additional wash step in order to remove the excess promastigotes that stayed extracellularly following 
in vitro infection. We found that the promastigotes of L. major, but not L. guyanensis and L. braziliensis parasites, survived at 35 
degrees Celsius (data not shown). Thus, macrophages were not washed after the infection. Consequently, we adapted and 
modified the previously established screening protocol of Aulner et al (Figure 1A) (19). To ensure the complete transition of 
intracellular promastigotes to amastigotes, macrophages were incubated with promastigote for two days. The time window for 
drug incubation was reduced from three to two days in order to increase the cell count in our assay. The pipeline of the screening 
assay comprised the dispensation of cells, parasites and drugs. Therefore, our pipeline included manual handling of assay plates 
during automated cell dispensing, automated plate washing, and automated compound pipetting. The time outside the cell 
incubator for the assay plates during these steps was less than one minute per plate for parasite and cell dispensation, and three 
minutes per four plates for compound dispensation.  
 
To detect intracellular amastigote and macrophage nuclei, we used DAPI, a fluorescent DNA intercalating dye. The 
nuclei of macrophages and parasites were segmented according to their size (Figure 1B). Heterochromatin regions of macrophage 
nucleus could wrongly be segmented as parasite nuclei by the software. To overcome this issue, macrophage nuclei were 
subtracted from the raw image after cell segmentation (Figure 1B). We excluded cells having nuclear stain but lacking 
cytoplasmic stain, and omitted the count of fragmented nuclei debris by setting size and shape restrictions (Figure 1B). Parasites 
that were within the boundaries of the macrophage cytoplasm were counted (Figure 1C). To increase sensitivity for the parasite 
and macrophage ratio calculation, cells that were located on the image boundaries were excluded (Figure 1C and 1D). 
 
Assay optimization  
We initially performed experiments to identify the optimal M-CSF concentration. The desired concentration would 
lead to macrophage survival, resulting in similar macrophage count in both infected and non-infected conditions without causing 
cell stacking. Our data showed that 50 ng/ml of M-CSF was enough to maintain an adequate macrophage number, and did not 
lead to discrepancies in cell number during parasite infection (Figure 2A and 2B). However, the addition of lower or higher 
concentrations of M-CSF leads to low cell yield and cell stacking, respectively (Figure 2A and 2B). We subsequently tested 
various MOI ratios to decipher an optimal parameter that results in a high infection rate and yields a similar cell count compared 
to non-infected controls (Figure 2C). These criteria were satisfied with a MOI of 10. 
 
Assay verification with reference compounds 
To test and validate the screening assay for its pharmacological relevance, we measured the half-maximal effective concentration 
(EC50) of two widely used anti-parasiticidal drugs, amphotericin B and miltefosine. Our results demonstrated that miltefosine 
was toxic to primary macrophages at concentrations above 15 micromolar, while we observe cytotoxicity to a certain extent for 
amphotericin B at any tested concentrations (Figure 3A and 3B). The EC50 values for amphotericin B and miltefosine were 0.2.5 
micromolar (plus or minus 0.0.6) and 4.1.0 micromolar (plus or minus 1.1.2), which coincide with previously published data 
(Figure 3A and 3B) (14, 17, 19-21).  
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Subsequently, we performed the HTDS protocol to measure the drug potency of miltefosine at 15 micromolar and 
amphotericin B at 1 micromolar using primary macrophages infected with LRV1-containing L. guyanensis parasites at various 
MOI. We found that the parasite per macrophage ratio was drastically different between vehicle control and drug-treated infected 
cells at a MOI of 10 (Figure 3C and 3D). Amphotericin B was used as a reference drug in the screening assay due to its consistent 
nanomolar range parasiticidal activity in other image-based drug screening assays. 
 
Drug screening  
We performed two independent HTDS screens against LRV1-containing L. guyanensis using a Prestwick chemical 
library. The screen has a 1.0.9% yield. Two infection experiments were performed with parasites isolated independently from the 
footpads of infected mice, and these parasite isolates were used in the HTDS procedure. The Z′-factor for each plate was over 0.5. 
(data not shown), indicating the robustness of the assay. The parasite counts of amphotericin B-treated infected and non-infected 
macrophages were similar, and were distinctly different from the parasite counts of DMSO-treated infected macrophages (Figure 
4A). The cell number of non-infected macrophages in wells from two-independent experiments was closely similar or identical 
(Figure 4B). Macrophage number together with parasite number varied between experiments (Figure 4B), however the infection 
ratio remained similar (data not shown). We identified fourteen compounds with parasiticidal activity of over 69 percent and over 
75 percent on average in two-independent screens (Table 1). A secondary validation screen was undertaken to measure the EC50 
of identified compounds (Figure 4C). We found that all compounds displayed an anti-parasiticidal activity of over 65% at a 10 
micromolar concentration, except dequalinium dichloride, sulconazole nitrate, tioconazole and oxiconozole nitrate (Figure 4C). 
Our data showed that antimycin A and disulfiram had parasiticidal potency at the nanomolar range without cellular toxicity.  
 
DISCUSSION 
 
In this study, we established a semi-automated high-throughput image-based drug screening technique in L. guyanensis 
LRV1-bearing infected macrophages considering the potential impact of LRV1 on treatment failure and relapses. The HTDS 
method offers unbiased, quantitative and statistical-powerful data. High-content based methods drastically reduced the duration 
of the primary drug screening procedure for leishmaniasis. The limitation in the HTDS method against Leishmania promastigotes 
is an additional washing step to remove excess extracellular promastigotes. We found that L. guyanensis, but not L. major, 
promastigotes were temperature sensitive, and could not survive outside of macrophages at 35 degrees Celsius. This feature of L. 
guyanensis facilitated the liquid handling in our HTDS protocol. Parasites were not transfected to express a fluorescent marker 
for detection in this protocol. The genetic alteration of parasites could require culturing with selection antibiotic for post-
transfection selection, which can interfere with drug screening analysis (20). We showed that DAPI staining was sufficient for 
detection of both parasite and macrophage nuclei. Moreover, cytosolic staining of macrophages allowed the quantification of 
intracellular amastigotes at the single cell level. The exclusion of cells with a cytosol stretching beyond the area of sight allowed 
us to have a more accurate parasite per macrophage ratio. 
 
We identified two drugs, disulfiram and antimycin A, with submicromolar anti-parasitic activity. Disulfiram is a 
lipophilic compound with a high octanol/water partition coefficient, facilitating lipid membrane permeability and increasing the 
bioavailability of drugs to amastigotes within the phagolysosome of macrophages. The inhibition of superoxide dismutase by 
disulfiram can also contribute to its high parasiticidal activity (22). Consistent with our results, a study identified disulfiram as a 
parasitoxic compound using promastigote based screening, and verified its potency using axenic amastigotes. However, the in 
vivo activity of disulfiram was relatively low, even though the drug treatment of mice started 3 days post infection. Disulfiram 
also displays a growth inhibitory effect against other parasites including Plasmodium falciparum (23),, Trichomonas vaginalis 
(24) and Tritrichomonas foetus (24). The metabolic byproduct of disulfiram has a metal chelator function, which can decrease the 
nephrotoxicity of platinum-based cisplatin in the combinational drug treatment of trypanosomiasis (25). It would be interesting to 
investigate the effects of disulfiram treatment in metal-based therapeutics for leishmaniasis. 
 
Antimycin A is an inhibitor of the mitochondrial complex III, and was reported to be parasitotoxic to L. donovani and 
L. mexicana parasites at nanomolar concentrations (20, 25). The inhibition of electron transport in the mitochondrial respiratory 
chain induces reactive oxygen species production (26). Thus, the treatment by antimycin A can enhance macrophage-mediated 
killing of parasites. A point mutation in the apocytochrome b gene of a L. tarentole parasite strain was associated to antimycin A-
resistance (27). This finding indicates that the therapeutical potency of antimycin A given to the possible emergence of drug-
resistant parasites. 
 
Some other identified compounds have  been reported to have antiparasitic activity. Astemizole, a known H1-histidine 
receptor antagonist, has been shown to inhibit proliferation of 3 different strains of P. falciparum that differ in their sensitivity to 
common antimalarial drugs (28). Bepridil hydrochloride is a calcium channel protein inhibitor that was shown to be parasitotoxic 
against various species of Leishmania in vitro but not in vivo (29). Dequalinium dichloride is an anti-microbial antiseptic 
medication with a large spectrum of bactericidal and fungicidal activity. In combination with chloroquine,  dequalinium 
dichloride was shown to be an efficient antimalarial agent (30), and displayed some mild activity against Trypanosoma brucei 
(31). Mefloquine hydrochloride is a medication used to prevent malaria. However, mefloquine hydrochloride was inactive against 
Leishmania amazonensis in vivo (32). One of the hits is pentamidine isethionate, which is a well-known anti-leishmanial drug 
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(33). Two azole-containing antifungal compounds including oxiconazole nitrate and tioconazole were reported to have 
leishmaniacidal activity in vitro (34, 35). 
 
In summary, the drug discovery process using HTDS allowed us to take into consideration two crucial parameters in 
parasite infection, namely the biology of the host cell and the interaction between host cells and parasites. This is relevant 
considering that drugs can have an indirect anti-parasitic effect by augmenting anti-parasiticidal activity of host cells, and can 
require the host cell metabolic processing to be active. Moreover, the concurrent analysis of drug-toxicity on host cells facilitates 
the hit identification, and the usage of genetically untouched parasites in the screening reduces the risk of data misinterpretation. 
This methodology is superior to classical drug screening techniques and presents a great potential for high-throughput drug 
screening against Leishmania parasites.  
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Figure 1. The pipeline of assay and data analysis. (A) The outline of experimental workflow. Bone-marrow progenitors were 
obtained from C57/BL6 mice and were cultured with M-CSF containing complete cell media for six days. Cells were counted 
using an automated cell counter, and dispensed in cleared bottom 96-well plates using an automated cell dispenser. Plates were 
incubated in 37 degrees Celsius, 5 percent CO2 incubator overnight, ensuring the adherence of macrophages. Stationary LRV1 
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containing Leishmania guyanensis promastigotes were cultured for 6 days and then dispensed on cells at MOI of 10. To increase 
the infection rate and boost the parasite growth, plates were cultured at 35 degrees Celsius, 5 percent CO2 incubator for the rest of 
the experimental procedure. Two days subsequent to infection, drugs were dispensed to the wells using a robotic liquid handler. 
Cells were processed for high content microscope acquisition two days post drug-treatment using a plate washer with plate-
stacking function and peristaltic pump: fixation with freshly made 4 percent PFA, pH 7.4.; washing with 1xPBS, pH 7.4.; and 
staining with DAPI and phalloidin. The image acquisition was performed using a high content microscope, and a robotic arm for 
plate gripping. (B) The nuclear image staining was converted to binary image, and cell nucleus was subtracted from this image to 
identify and define parasites. (C) Cell area was defined as the combination of nuclear and cytosolic staining in a binary image. 
The cells that had cytosol bordering the edges of image were removed. (D) The final processed image contained segmented 
objects including cytosol (yellow), cell nucleus (pink), and parasite nuclei (blue). 
 
Figure 2. Optimization of cell culture conditions and infection. (A-B) In HTDS procedure, macrophages were cultured with 
various amount of MCSF ranging from 1.5.6 to 400 ng/ml with two-fold increments. (A) Image displayed phalloidin staining and 
forty-nine composite images from each well. (B) Cells were counted using an automated image analysis. Graph shows the total 
cell count in obtained images per well. (C) HTDS were performed with macrophages that were supplemented with 50ng/ml 
MCSF, and were infected with parasites at various MOI. Graph displays macrophage cell number on the left-axis, and parasite 
per macrophage ratio on the right-axis. Data displays one significant independent experiment with three biological replicates. 
 
Figure 3. Reference drug optimization. Eight-point dose response curves of (A) Amphotericin B and (B) miltefosine were 
generated using the HTDS protocol. (C-D) HTDS protocol were performed, and macrophages were treated with vehicle control 
(DMSO), 15 micromolar miltefosine, or 1 micromolar amphotericin B. Graph is a representative of three independent 
experiments (A-B) or of one with three technical replicates (C-D). 
 
Figure 4. Primary and secondary HTDS screening. (A) Plot of the average parasite number (Y-axis) in forty-nine images of 
controls from the two independent primary screenings. (B) Plot of the average parasite number (X-Axis) and average macrophage 
number (Y-axis) in forty-nine images of controls the two independent primary screenings. (C) Eight-point dose response curves 
of compounds that displayed over sixty nine percent anti-leishmanial activity in two independent screens. 
 
 
Table 1. Compounds that displayed over sixty nine percent anti-parasitic activity in two independent HTDS  
Compounds 
Anti-Leishmanial Activity (percent %) 
1st HTDS 2nd HTDS 
Antimycin A 93.1.9 95.2.4 
Astemizole 83.6.1 92.9.7 
Bepridil hydrochloride 93.6.6 83.3.5 
Ciclopirox ethanolamine 94.6.5 95.6.5 
Clofilium tosylate 83.0.3 76.7.0 
Dequalinium dichloride 80.5.3 69.6.3 
Disulfiram 90.8.9 87.1.2 
Mefloquine hydrochloride 93.1.4 69.8.3 
Oxiconazole Nitrate 91.6.9 94.7.2 
Pentamidine isethionate 84.1.1 81.0.0 
Perospirone 91.8.5 91.8.5 
Prenylamine lactate 94.5.5 89.1.8 
Sulconazole nitrate 95.6.2 93.6.5 
Tioconazole 94.4.5 96.0.3 
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